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Abstract: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that causes loss
of joint function and significantly reduces quality of life. Plasma metabolite concentrations of
disease-modifying anti-rheumatic drugs (DMARDs) can influence treatment efficacy and toxicity.
This study explored the relationship between DMARD-metabolising gene variants and plasma
metabolite levels in RA patients. DMARD metabolite concentrations were determined by tandem
mass-spectrometry in plasma samples from 100 RA patients with actively flaring disease collected
at two intervals. Taqman probes were used to discriminate single-nucleotide polymorphism (SNP)
genotypes in cohort genomic DNA: rs246240 (ABCC1), rs1476413 (MTHFR), rs2231142 (ABCG2),
rs3740065 (ABCC2), rs4149081 (SLCO1B1), rs4846051 (MTHFR), rs10280623 (ABCB1), rs16853826
(ATIC), rs17421511 (MTHFR) and rs717620 (ABCC2). Mean plasma concentrations of methotrexate
(MTX) and MTX-7-OH metabolites were higher (p < 0.05) at baseline in rs4149081 GA genotype
patients. Patients with rs1476413 SNP TT or CT alleles have significantly higher (p < 0.001) plasma
poly-glutamate metabolites at both study time points and correspondingly elevated disease activity
scores. Patients with the rs17421511 SNP AA allele reported significantly lower pain scores (p < 0.05)
at both study intervals. Genotyping strategies could help prioritise treatments to RA patients most
likely to gain clinical benefit whilst minimizing toxicity.
Keywords: rheumatoid arthritis; SNP; DMARD; methotrexate; pharmacogenomics
1. Introduction
Rheumatoid arthritis (RA) is the most common chronic autoimmune inflammatory arthritis,
affecting approximately 0.3–1% of the world’s population [1,2]. The disease primarily affects the
articular joints, causing swelling, stiffness, joint destruction [3], loss of function in joints [4], disability
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and a significantly lower quality of life. To prevent irreversible joint damage resulting in substantial
disability, it is important to introduce disease-modifying anti-rheumatic drugs (DMARDs) early after
onset and failure of non-steroidal anti-inflammatory treatment.
Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) such as
methotrexate (MTX), hydroxychloroquine (HCQ), cyclosporin, sulfasalazine (SSZ) and leflunomide are
commonly used mainstays of the disease; however, it is widely known that a significant proportion of
patients with RA often show poor or inadequate therapeutic response to csDMARDs [5]. The anti-folate
MTX is the cheapest drug in treatment of RA and is often the first-line treatment [6]; however, only
55% of patients remain on this drug for more than 2 years due to a build-up of non-response or the
accumulation of various adverse side effects [6,7]. MTX is subject to significant metabolic activity in the
body; the polyglutamated derivatives of MTX are selectively retained in cells, therefore lengthening
the activity of the drug which complicates treatment management, since patients would continue
taking their daily drug dosage oblivious to the fact that their circulating drug levels are still high,
potentially contributing to undesirable cytotoxic effects [8,9]. MTX is converted in hepatic parenchymal
cells resulting in the 2- through 4-glutamate residues derivatives or the drug is catabolised to the
7-hydroxy-methotrexate (MTX-7-OH) form [10]. More than 10% of a dose of methotrexate is oxidised
to MTX-7-OH, irrespective of the route of administration [11]. The MTX-7-OH metabolite is extensively
(91 to 93%) bound to plasma proteins, in contrast to the parent drug (only 35 to 50% bound) and
contributes to inactivity of the drug or poor response to treatment [11].
When non-response has been confirmed, NICE clinical guidelines recommend switching to the
more costly biological disease-modifying anti-rheumatic drugs (bDMARDs) [5,12,13]. Various studies
indicate that treat-to-target strategies which aim to reduce disease activity shortly after diagnosis result
in better long term outcomes and can minimise permanent joint damage, thus there is a genuine need
for earlier identification of patients who do not respond well to csDMARDs treatments [6].
It is estimated that 15–30% of variation in drug responses are attributable to genetic or
single-nucleotide polymorphisms or SNPs [14]. Not all SNPs are functional; some are in non-coding
areas (introns) and there is a variety of ways that a SNP can affect or inhibit downstream transcription
factor, gene or protein function [15]. The promise of pharmacogenomics is that identification of SNPs
and associated risk alleles could identify patients who may be susceptible to accumulating cytotoxic
levels of a drug during therapy (as in the polyglutamate derivatives of MTX) or when certain metabolite
levels accumulate rendering a drug as inactive (as in MTX-7-OH).
In this study, we sought to determine the metabolite levels in RA patients taking DMARDs.
We then carried out genotyping of 10 SNPs known to influence the metabolic pathways of DMARDs in
arthritis. Our aim was to determine if genetic variations or polymorphisms associate with metabolite
levels. This could help design studies to improve clinical management, which risk stratify patients at
greater predisposition of forming ineffective or potentially harmful metabolite levels, by adequately
planning ahead the appropriate drug and dosage.
2. Materials and Methods
2.1. Participant Recruitment
The research team at Ulster University collaborated with rheumatologists from the Western
Health and Social Care Trust (WHSCT) to design, conduct and recruit patients to the study. Informed
consent to participate was obtained from all RA patients enrolled to the study. One hundred patients
identified using following inclusion/exclusion criteria were recruited into the prospective observational
cohort study: Remote Arthritis Disease Activity MonitoR (RADAR); ClinicalTrials.gov Identifier:
NCT02809547. Inclusion criteria: aged between 18–90 years, diagnosed with RA (according to
American College of Rheumatology criteria [5,16]), diagnosed with RA for a minimum of 1 year and
maximum 10 year duration, active disease flares on a regular basis, and receiving a disease-modifying
anti-rheumatic drug (DMARD). Exclusion criteria: any other inflammatory conditions, any infections
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or trauma during study period, and have restricted hand function (determined by clinical team). Office
for Research Ethics Committees Northern Ireland (ORECNI) (16/NI/0039), Ulster University Research
Ethics Committee (UREC) (REC/16/0019) and WHSCT (WT/14/27) approvals were obtained for the
study. Informed consent was obtained from all RA patients enrolled to the study.
2.2. Whole Blood and Dried Blood Spot Sample Collection
Venepuncture whole blood samples as part of the normal routine care pathway were forwarded to
the hospital laboratories for multiple tests including CRP, ESR, Bilirubin, Liver enzymes and full blood
count. An additional 5-mL EDTA tube of blood was collected from each of the 100 participants for DNA
genotype and drug metabolite analyses within the RADAR study. Samples were collected at both study
baseline and at a 6-week follow-up appointment at an outpatient rheumatology clinic for all participants.
Additionally, a sub cohort of 30 of the above participants were supplied with a kit containing sufficient
dried blood spot (DBS) cards [17], finger lancets and pre-paid and addressed postal envelopes with
desiccant and biohazard sealable pouch to send a weekly samples (approximately 3–5 droplets of
blood ~20 µL each) from home to the NICSM laboratory for drug metabolite analysis. Finger lancet
blood droplets were deposited onto dried blood spot (DBS) Protein Saver 903TM cards (Whatman, GE
Healthcare Life Sciences, Buckinghamshire, UK), pre-treated with a protein stabiliser coating.
2.3. Nucleic Acid Isolation from Peripheral Blood
Total DNA was isolated from peripheral blood samples using TRIzol reagent (TRIzol LS Reagent,
Thermo Fisher Scientific, Basingstoke, UK. cat. No 10296-010) according to manufacturer’s directions.
Total DNA concentration was estimated by spectrophotometry (NanoVue Plus—GE Health Care,
Buckinghamshire, UK).
2.4. Mass-Spectrometry Analysis
Determination of methotrexate (MTX) metabolites was performed using a liquid extraction
surface analysis (LESA) coupled with nanoESI-triple quadruple mass spectrometer (QQQ) using
Triversa nanomate (Advion, New York, NY, USA) and API 4000 QQQ Mass Spectrometer (AB Sciex,
Cheshire, UK). Control MTX metabolites and internal standards were from Schircks Laboratories
(Jona, Switzerland).
Quantitation for MTX and MTX metabolites was performed by the matrix-matched standards
approach using an intensity ratio (ISTD/MTXs) calibration (10–2000 nM). Signal for each metabolite
was the average of n = 2 (duplicate injection). A total of 5 nM was selected as LLOD (S/N ~ 3) for MTX,
7-OH MTX and MTX-PG2 and 8 nM was selected for MTX-PG3 to PG5; 10 nM was selected as LLOQ
for MTX and all metabolites (S/N ~ 10). Intra- and inter-day precision was assessed at both 50 and
500 nM and coefficient of variation (CV) for MTX metabolites ranged from 2.0–7.2%. Linear regression
coefficient (R2) of the back-calculated concentration against the nominal concentration for MTX and its
metabolites was above 0.995.
Determination of sulfasalazine metabolites and teriflunomide, analysis was performed by liquid
chromatography tandem mass spectrometry (LC-MS/MS) using a HP 1200 LC (Agilent, Palo Alto, CA,
USA) and a Quattro micro mass spectrometer (Micromass, Manchester, UK). Control sulfasalazine
metabolites, teriflunomide and internal standard were obtained from Sigma Aldrich, Gillingham, UK.
Quantitation of sulfasalazine, its metabolites and teriflunomide was performed by the matrix-matched
standards approach using an intensity ratio (ISTD/Analyte) calibration (5–500 µg/L). Signal for each
metabolite was the average of n = 2 (duplicate injection). 5 µg/L was selected as LLOD (S/N > 5) for
metabolites and 10 µg/L was selected as LLOQ for all metabolites (S/N > 10).
Intra- and inter-day precision was assessed at both 20 and 100 µg/L and coefficient of variation
(CV) for sulfasalazine metabolites ranged between 1.4–5.8%. Linear regression coefficient (R2) of the
back-calculated concentration against the nominal concentration for sulfasalazine, its metabolites and
teriflunomide was above 0.992.
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Separation of targeted analytes was carried out by reverse phase chromatography using a C18
column in gradient mode. Quantitation of all analytes were performed in positive ion mode multiple
reaction monitoring (MRM) using matrix-matched standards and stable isotope ratios. All Mass
Spectrometry methods were validated according to ICH Guidance for selectivity/specificity, limit of
detection/quantitation (LLOD/LLOQ), linearity and precision [18]
2.5. Endpoint-Genotyping Using Taqman Assay
Endpoint genotyping analysis was carried out using the LightCycler 480 real-time PCR system
(ROCHE). The assay is based on the competition during annealing between probes detecting the
wild type and the mutant allele. The 5′-exonuclease activity of DNA polymerase cleaves the doubly
labelled Taqman probe hybridised to the SNP-containing sequence, once cleaved, the 5′-fluorophore
is separated from a 3′-quencher. Two allele-specific probes carrying different fluorophores (VIC®,
emission: 554 nm and FAMTM, emission: 518 nm) permits SNP determination in a single well without
any post-PCR processing. Genotype is determined from the ratio of intensities of the two fluorescent
probes at the end of amplification (endpoint instead of the entire cycle in conventional PCR).
2.6. Taqman Probes Used for Single-Nucleotide Polymorphism Genotyping
The concentration and integrity of the genomic DNA were assessed by microvolume
spectrophotometer (NanoDrop 2000; Thermo Fisher Scientific). DNA samples were genotyped by the
following TaqMan SNP genotyping assays [MTHFR-rs1476413, Assay Identification (ID) C_8861304_10;
RS1-rs 2231142, Assay Identification (ID) C_354526997_10; ABCC2-rs3740065, C_22271640_10;
SLCO1B1-rs4149081, Assay Identification (ID) C_1901759_20; MTHFR-rs4846051, Assay Identification
(ID) C_25763411_10; ABCB1-rs10280623, Assay Identification (ID) C_30537012_10; ATIC-rs16853826,
C_33295728_10; MTHFR-rs17421511, Assay Identification (ID) C_32800189_20; ABCC2-rs717620,
C_2814642_10; ABCC1-rs246240, Assay Identification (ID) C_1003698_10; Life Technologies Ltd.).
2.7. Validation of Polymorphisms by Pyrosequencing
Validation of SNP genotyping results from the Taqman assays was performed on a subset of
samples using pyrosequencing. Due to the high number of SNPs to cover, a method using a universal
biotinylated primer was employed [19]. Briefly, this method involves the use of standard target specific
primer pairs with a universal M13 sequence at the 5′ end of one of the primers. A third, biotinylated
M13-targeting primer is included in the PCR amplification reaction, leading to incorporation of biotin
into the PCR product without the need for individual biotin labelling of each individual primer pair
and thus lowering the cost of pyrosequencing considerably. A list of primers used for pyrosequencing
are shown in Table S3.
PyroMark Assay Design Software 2.0 (Qiagen) was used for primer design in the SNP calling
assay design format. PCR amplification was carried out using the Pyromark PCR kit (Qiagen) in 25 µL
total volumes with 10–20 ng DNA and final concentrations of 0.2 mM for each primer. Standard PCR
cycling conditions were used as per manufacturer’s instructions and were consistent for all samples
and targets. PCR products were checked by agarose gel electrophoresis and those with a positive single
band of the expected size were taken forward into pyrosequencing on the Pyromark Q48 (Qiagen)
using standard manufacturers protocols and the instrument run setting for SNP calling.
2.8. Statistics and Sample Size Calculations
Statistical analysis was carried out with SPSS ver.25 (IBM Corp, NY, USA), SciPy module (ver. 1.3)
for Python (version 3.7.2) and R (version 3.60) with p < 0.05 considered as statistically significant, all
within 95% confidence intervals. Descriptive statistics were used to characterise the variability in
mean MTX, MTX-7-OH and MTX2PG–5PG and MTXtotal concentrations between different genotype
groups of patients. Normality of data was determined using the Shapiro-Wilks test in SPSS (ver. 25)
prior to employing the Kruskal–Wallis non-parametric (distribution free) one-way ANOVA, with
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Dunn–Bonferroni post hoc test to assess differences between genotype group means using GraphPad
Prism version 8.0.0 for Windows (GraphPad Software, San Diego, CA, USA, www.graphpad.com).
The Hardy-Weinberg equilibrium was assessed for SNPs with significant clinical associations in
the methotrexate treated cohort. A Chi-square test with Benjamini-Hochberg adjusted p values was
used to assess if there were significant differences between the genotype frequencies expected from
dbGAP European population and those observed. Power was calculated for the same SNPs using the
GENPWR package [20] within R (v 4.0.2), using the linear regression model (with alpha at 0.05) since
the goal was to calculate power in a continuous outcome (metabolite levels) between genotypes.
3. Results
3.1. Study Population
A total of 100 participants, n = 68 female and n = 32 male, with active rheumatoid arthritis were
enrolled to this study (Table 1). The mean age of study participants was 59.5 years with a mean disease
duration of 6 years and mean baseline disease activity score (DAS28ESR) of 3.6.
Table 1. RADAR Study Cohort Demographics. Clinical and laboratory feature summary across n = 100
participants. yr: years; Anti-CCP: anti-cyclic citrullinated peptide; ESR: erythrocyte sedimentation
rate; DAS28: disease activity score across 28 joints; RBC, red blood cell (count); Hb: haemoglobin;
WBC: white blood cells; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline
phosphatase; SD: Standard deviation.
Mean SD
Gender, male/female 32/68 -
Age, yr 59.5 12.6
Disease duration, yr 6.0 3.9
C-reactive protein, mg/L 7.9 11
Rheumatoid factor, n positive 63 -
Anti-CCP, n positive 53 -
ESR (mm/h) 15 15
DAS-28 ESR 3.6 1.5
RBC (cells/mL) 4.5 1.2
Hb (g/100 mL) 134 13
WBC (cells/mL) 6.8 2.3
Neutrophils (cells/mL) 4.4 1.9
Lymphocytes (cells/mL) 1.7 1.4
Platelets (cells/mL) 254 68
ALT (u/L) 23 11
AST (u/L) 24 9.4
ALP (u/L) 80 22
Bilirubin mg/L 8.2 5.6
A subgroup of n = 66 participants (n = 46 female) were treated with weekly methotrexate at
baseline was identified for subsequent genotype association analyses. Baseline and 6-week follow-up
drug dose information is summarized in Table S2A,B for this main subgroup. A smaller, partially
overlapping, subgroup of n = 27 participants (n = 20 female) being treated with daily sulfasalazine at
baseline was also identified for subsequent analyses (Table S2B).
3.2. Single-Nucleotide Polymorphisms Analysed in this Study
Ten SNPs were analysed in this study, previous studies have linked these SNPs to various clinical
consequences observed in RA patients being treated with DMARDs, documented in the PharmGKB
database [21,22]. SNP genotypes were determined by endpoint PCR assay and allele specific probes
(Figure 1). The SNPs characteristics and frequencies in the study cohort are summarised in Table 2.
J. Pers. Med. 2020, 10, 149 6 of 14
Table 2. Characteristics of the single nucleotide polymorphisms analysed in the RADAR study cohort. Ref: reference; Alt: alternative; dbGAP: database of Genotypes





SNP Variant Locale Gene Clinical Consequences Alleles(Ref > Alt) −/− +/− +/+
rs10280623 Intron ABCB1 Associated with MTX toxicity T > C C = 0.1933 (n = 5,216) 64 21 14
rs246240 Intron ABCC1 Low response to MTX A > G G = 0.153169 (n = 131,156) 6 25 69
rs717620 Non-coding Transcript ABCC2 Increased time needed to reach therapeutic level C > T T = 0.198186 (n = 137,144) 11 24 65
rs3740065 Intron ABCC2 Increased risk of MTX toxicity A > G G = 0.108811 (n = 128,976) 1 10 87
rs2231142 Intron Missense ABCG2 SNP causes higher toxicity with combination treatments G > T T = 0.10454 (n = 88,504) 8 21 71
rs16853826 Intron ATIC ATIC rs16853826 variant associated with toxicity G > A A = 0.12231 (n = 10,972) 72 20 8
rs4846051 Codon Synonymous MTHFR Increased risk of MTX toxicity A > G G = 0.023185 (n = 117,404) 0 0 100
rs17421511 Intron MTHFR Positive response to MTX treatment (GG) G > A A = 0.1674 (n = 5990) 36 46 16
rs1476413 Intron MTHFR Positive response to MTX treatment (CC) C > T T = 0.270570 (n = 131,256) 15 24 61
rs4149081 Intron SLC081 Increased risk of MTX toxicity G > A A = 0.168487 (n = 136,218) 51 22 27
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Figure 2). Table 3 indicates that within the n = 66 methotrexate treated subgroup, n = 17 participants 
with the minor homozygote genotype AA in rs4149081 have a significantly lower mean plasma MTX-
7-OH concentration compared to the GA genotype group (p = 0.002) at baseline. Although a similar 
trend is observed at the 6-week follow-up, this was not statistically significant. The GA genotype 
Figure 1. Endpoint polymorphism genotype assay. Genotype were determined for the listed
polymorphisms in the RADAR study cohort (n = 100) from the ratio of fluorescent intensities (nm) of
the two-allele specific Taqman probes (VIC and FAM) at the end of PCR amplification. Clusters in upper
and lower quadrants represent groups of individuals with a homozygous genotype for either allele;
the middle quadrant represents individuals with heterozygous genotype. (A) rs246240, (B) rs717620,
(C) rs1476413, (D) rs17421511, (E) rs2231142. (F) rs3740065, (G) rs4149081, (H) rs4846051, (I) rs10280623,
(J) rs16853826. Genotypes were also confirmed by pyrosequencing in selected individuals. Genotype
frequency is summarized in Table 1.
3.3. Methotrexate and Sulfasalazine Metabolite Polymorphism Associations
The data strongly suggest plasma concentrations of methotrexate and sulfasalzine metabolites
are associated with the allelic genotype for 2 particular polymorphisms, rs4149081 and rs1476413 (see
Figure 2). Table 3 indicates that within the n = 66 methotrexate treated subgroup, n = 17 participants
with the minor homozygote genotype AA in rs4149081 have a significantly lower m an plasma
MTX-7-OH concentration compared to the GA genotype group (p = 0.002) at baseline. Although
a similar trend is observed at the 6-week follow-up, this was not sta istically significant. The GA
genotype group mean concentrations of MTX and MTX-7-OH are significantly higher than those
observed in the GG genotype group (p = 0.01 and p = 0.038, respectively; Figure 2A,B). The baseline
mean blood bilirubin concentration was the only feature observed at significantly higher levels in the
rs4149081 AA genotype, relative to the GG genotype group (p = 0.020; Figure 2C).
A total of n = 8 participants with the rs1476413 homozygous major allele genotype CC have
significantly lower (p = 0.012) group mean plasma MTX-7-OH concentration, compared to the CT
genotype group (Table 3) at the 6-week follow-up sessions. No significant difference was observed at
baseline. The mean plasma concentration of tetraglutamate MTX metabolites are also significantly lower
in the rs1476413 CC genotype group at both baseline (p = 0.02) and 6-week follow-up appointments
(p = 0.008; Figure 2F,G and Table 3).
A total of n = 6 participants with the minor allele genotype AA in the SNP rs17421511
(Supplementary Figure S1A,B) show significantly higher mean plasma concentration (p = 0.013) of
sulfapyridine at the 6-week follow-up appointment period only, relative to GG and GA genotype groups.
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Table 3. Methotrexate Treated Cohort SNP associations. Features including plasma drug metabolite, 
blood cell counts and clinical outcome measures which had statistically significant associations for 
the four polymorphisms rs4149081, rs1476413, rs2231142 and rs17421511 in n = 66 methotrexate 
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group (n = females/total) indicated. Statistically significant differences between genotype group 
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Figure 2. rs4149081 and rs1476413 genotype associations. Statistically significant associations between
two polymorphisms, plas a drug etabolite concentration, other laboratory and clinical outcome
measures are shown for individual genotypes in methotrexate treated participants (n = 66). Each
symbol represents an individual participant of the genotype indicated on the x axes. Data grouped by
rs4149081 genotypes: (A) baseline plasma concentration of unmetabolised methotrexate, (B) baseline
plasma concentration of 7-hydroxy-methotrexate, (C) baseline bilirubin blood concentration, (D) weekly
plasma concentrations (log scale) of listed methotrexate metabolites (PGs: polyglutamate subtypes) of
a rs4149081 GA genotype participant. Data grouped by rs1476413 genotypes: (E) 6-week follow-up
plasma concentration of 7-hydroxy-methotrexate, (F) baseline and (G) 6-week follow-up plasma
concentrations of long-chain methotrexate 4-glutamate, (H) baseline and (I) 6-week follow-up disease
activity (DAS28ESR) scores. Statistically significant differences between genotype group means are
indicated by horizontal bars and an asterisk used to summarise p values adjusted by Bonferroni’s
multiple comparison test: (*) p < 0.05; (**) p < 0.005 (descriptive statistics data shown in Table 3).
Red horizontal bar represents genotype group mean; error bars represent standard deviation. MTX:
methotrexate; BL: baseline; 6w: 6-week follow-up.
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Table 3. Methotrexate Treated Cohort SNP associations. Features including plasma drug metabolite, blood cell counts and clinical outcome measures which had
statistically significant associations for the four polymorphisms rs4149081, rs1476413, rs2231142 and rs17421511 in n = 66 methotrexate treated participants. Mean data
for each genotype group with number of individuals and females per group (n = females/total) indicated. Statistically significant differences between genotype group
means were initially assessed by ANOVA and then an adjusted by Bonferroni’s multiple comparison test performed for specified genotype group mean comparisons;
asterisk used to summarise p values: (*) p < 0.05; (**) p < 0.005. Features with significant differences between genotype means are graphed in Figures 2 and 3. Unlisted
features had no statistically significant association with any SNP (see Table S1). BL: baseline; 6wk: six-week follow-up; SD: standard deviation; ns: not significant.







rs4149081 GG (n = 25/36) GA (n = 11/13) AA (n = 10/17)
MTX (BL) nM 28.0 7.5 35.8 7.8 28.9 8.2 0.011 GG vs. GA 0.010 **
MTX (6wk) nM 26.0 10.6 34.1 11.5 25.9 10.2 0.058 GG vs. GA 0.071 ns
MTX-7-OH (BL) nM 20.6 4.8 24.8 5.3 18.2 4.8 0.003 GG vs. GA 0.038 *
GA vs. AA 0.002 **
MTX-7-OH (6wk) nM 19.1 6.8 23.3 7.2 17.3 7.6 0.079 GG vs. GA 0.239 ns
GA vs. AA 0.084 ns
Bilirubin (BL) mg/L 6.7 2.623 8.1 6.211 11.9 10.15 0.024 GG vs. AA 0.020 *
Bilirubin (6wk) mg/L 6.6 2.392 7.8 3.76 10.2 8.64 0.059 GG vs. AA 0.054 ns
rs1476413 CC (n = 6/8) CT (n = 13/16) TT (n = 26/42)
MTX-7-OH (BL) nM 19.8 5.6 21.2 5.7 20.1 5.9 0.791 CC vs. CT >0.999 ns
MTX-7-OH (6wk) nM 12.7 6.5 22.3 5.2 18.7 8.2 0.015 CC vs. CT 0.012 *
MTX 4PG (BL) nM 19.8 5.6 37.7 16.2 32.4 15.1 0.024 CC vs. CT 0.020 *
MTX 4PG (6wk) nM 19.0 15.6 42.4 16.8 30.2 17.5 0.007 CC vs. CT 0.008 **
DAS28ESR (BL) 2.3 1.5 4.0 1.6 3.6 1.5 0.047 CC vs. CT 0.049 *
DAS28ESR (6wk) 3.0 1.4 4.2 1.6 4.2 1.2 0.051 CC vs. CT 0.090 ns
rs2231142 GG (n = 3/6) GT (n = 12/15) TT (n = 30/45)
RBC (BL) mill./uL 4.4 0.4 4.1 0.3 4.4 0.4 0.050 GT vs. TT 0.044 *
RBC (6wk) mill./uL 4.4 0.3 4.1 0.3 4.4 0.4 0.042 GT vs. TT 0.044 *
ALP (BL) u/L 78.3 26.5 66.6 20.3 84.2 20.2 0.023 GT vs. TT 0.019 *
ALP (6wk) u/L 84.3 31.4 72.7 15.2 85.1 23.0 0.184 GT vs. TT 0.208 ns
Lymphocytes (BL) (cells/ml) 2.1 1.2 1.4 0.3 1.6 0.5 0.048 GG vs. GT 0.043 *
Lymphocytes (6wk) (cells/ml) 2.2 1.2 1.4 0.4 1.6 0.6 0.023 GG vs. GT 0.019 *
rs17421511 GG (n = 18/26) GA (n = 24/31) AA (n = 4/9)
PgPain (BL) % 44.8 30.4 53.8 31.5 22.1 26.6 0.037 GA vs. AA 0.033 *
PgPain (6wk) % 45.4 27.9 55.9 32.8 22.2 23.4 0.016 GA vs. AA 0.013 *
DAS28ESR (BL) 3.7 1.6 3.9 1.5 1.8 0.6 0.002 GA vs. AA 0.002 **
GG vs. AA 0.005 **
DAS28ESR (6wk) 4.1 1.1 4.2 1.4 3.1 1.5 0.088 GA vs. AA 0.097 ns
GG vs. AA 0.159 ns
ALT (BL) u/L 20.6 10.1 21.8 11.1 32.0 15.9 0.047 GG vs. AA 0.048 *
ALT (6wk) u/L 21.7 10.7 20.5 9.3 27.1 12.4 0.252 GG vs. AA 0.534 ns
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3.4. Clinical and Laboratory Feature Polymorphism Associations
While the average red blood cell counts (RBC) remain within reference ranges in both men and
women in this study (Table 1), there is a modest but statistically significant decrease in mean RBC
levels in the n = 15 participants with the rs2231142 heterozygous genotype GT compared to the TT
genotype group at both study time points (p = 0.044; Table 3, Figure 3A,B). Mean alkaline phosphatase
concentration is also significantly lower at baseline in the rs2231142 GT genotype group, relative to the
TT genotype participants (p = 0.019; Figure 3C). In the smaller group of n = 6 rs2231142 GG genotype
participants, mean lymphocyte counts are significantly higher than the GT genotype group, again at
both time points (p = 0.043, p = 0.019; Figure 3D,E).
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Figure 3. rs2231142 and rs17421511 genotype associations. Statistically significant associations between
two polymorphisms and other laboratory and clinical outcome measures are shown for individual
genotypes in methotrexate treated participants (n = 66). Each symbol represents an individual
participant of the genotype indicated on the x axes. Data grouped by rs2231142 genotypes: (A) baseline
and (B) 6-week follow-up red blood cell (RBC) count, (C) baseline blood alkaline phosphatase (ALP)
concentration, (D) baseline and (E) 6-week follow-up lymphocyte count. Data grouped by rs17421511
genotypes: (F) baseline and (G) 6-week follow-up patient assessed pain (PgPain) levels, (H) baseline
disease activity (DAS28ESR) scores, (I) baseline blood alanine aminotransferase (ALT) concentration.
Statistically significant differences between genotype group means are indicated by horizontal bars and
an asterisk used to summarise p values adjusted by Bonferroni’s multiple comparison test: (*) p < 0.05;
(**) p < 0.005 (descriptive statistics data shown in Table 3). Red horizontal bar represents genotype
group mean; error bars represent standard deviation. BL: baseline; 6w: 6 weeks follow-up.
Mean patient-reported general pain (PgPain) scores are significantly lower in n = 9 participants
carrying the rs17421511 AA genotype at baseline (p = 0.033) and at the 6-week follow-up appointment
(p = 0.013) compared to those with the GA genotype (Figure 3F,G). This trend is also reflected in
significantly lower mean baseline DAS28ESR scores in participants carrying the rs17421511 AA
genotype, relative to the GA and GG genotype groups (p = 0.002 and p = 0.005 respectively; Table 3,
Figure 3H), though scores even-out at the 6-week follow-up period among all three genotypes. The
baseline mean alanine aminotransferase (ALT) was recorded at significantly higher blood concentrations
in the rs17421511 AA genotype group, relative to the GG genotype participants (p = 0.048; Figure 3I).
The Benjamini–Hochberg-adjusted Chi-square test p-values showed no statistically significant
differences between the genotype frequencies observed and those expected from dbGAP European
population: rs4149081, padj = 0.515; rs 1476413, padj = 0.945; rs17421511, padj = 0.711; rs2231142,
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padj = 0.9454. The power calculated for each of these SNPs at p < 0.05 was: rs4149081, 0.96; rs 1476413,
0.95; rs17421511, 0.97; rs2231142, 0.94.
4. Discussion
This study investigates the influence of ten well-characterised SNPs in RA and we have tried to
correlate this with the appearance and accumulation of metabolites measured in the plasma of patients
taking DMARDs such as methotrexate and or sulfasalazine. The in vivo pharmacotherapy of DMARDS
and potential response biomarkers in RA have been previously described [6,23–25], however there
studies of potential associations between circulating csDMARD levels and specific genetic variants
remain limited in RA patients.
Typically, methotrexate treatment may cause elevations in serum AST and ALT, long term therapy
has also been linked to development of fatty liver disease, fibrosis, cirrhosis, nephrotoxicity, and
renal failure [26]. However, under active consultant-led clinical management, these effects are largely
minimised. The mean values of all clinical biomarkers, liver enzyme and blood component cell-counts
(Table 1) are within recommended normal reference ranges when viewed across all of the study
participants. However, mean ALT was significantly higher at baseline in the methotrexate treated
subgroup of participants with the rs17421511 AA genotype, albeit the potential effect of multiple drug
combinations was not investigated in this subgroup.
Although the average RBC count when taken from all participants appear to be within normal
ranges (Table 1), participants with the GT allele in the rs2231142 SNP have significantly decreased
erythrocyte counts in their circulation compared to those with the homozygous alleles methotrexate
affects folic acid metabolism, thus patients taking MTX may show variations in their mean corpuscular
volume (MCV) of red blood cells (RBC), therefore resulting in megaloblastic anaemia.
RBCs retain MTX as the polyglutamate derivatives throughout their lifespan [27,28]. While
normal RBC levels are between 4.7 to 6.1 million cells per microlitre (mill.c/µL) for men and between
4.2 to 5.4 mill.c/µL in women, the slight decrease shown in heterozygous rs2231142 SNP patients is
statistically significant. However, the lower mean haemoglobin levels observed in the rs2231142 GT
genotype is not statistically significant and there is no correlation with disease activity score as may
have been anticipated in anaemia of chronic disease.
Apart from the impact of sex-linked genes in RA, the diversity in our genomes are partially
accountable for the heterogeneity in the clinical presentation of synovitis among patients [29]. The
genetic influence in RA is particularly strong, the heritability in RA is estimated to be around 60% [29]
and with the high diversity of clinical presentations observed in RA, the goal in treatment would be
to stratify patients according to their genetic profile and clinical outcome, eventually formulating a
genetic-risk based personalised treatment management protocol.
MTX is an anti-folate drug, with anti-proliferative and anti-inflammatory effects, by inhibition
of folate and adenosine pathways and inhibition of purines and pyrimidines synthesis [30–32].
Approximately 80–90% of methotrexate is primarily excreted by the kidneys [33]. MTX is converted in
hepatic parenchymal cells of some patients resulting in the 2- through 4-glutamate residues derivatives
or the drug is catabolised to the MTX-7-OH form.
Though not observed consistently on both study time points, participants with the AA allele in
rs4149081 and CC allele in rs1476413 can have significantly lower mean plasma levels of MTX-7-OH in
their plasma circulation. Since some genotype groups are modest in size, the potential for differences
in the mean MTX dose between genotype groups was analysed, though no significant difference was
observed (Table S2). Furthermore, only a weak correlation exists between MTX dose and circulating
MTX-7-OH (r2 = 0.08213). Increasing levels of MTX-7-OH is known to inhibit the clinical responsiveness
of RA patients to the MTX drug and therefore, reduced levels of this metabolite could signify a better
clinical response to MTX [34]. Thus, with genetic profiling of expanded csDMARD naïve RA cohorts,
it would be interesting to further investigate clinical responsiveness to MTX in these genotypes.
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The 2- through 4-polyglutamate MTX metabolite-derivatives are selectively retained in cells
and participants with the TT or CT alleles in the rs1476413 SNP tend to show significantly higher
mean plasma levels of the tetraglutamate metabolite. A significantly higher mean DAS28 is observed
only at study baseline in the rs1476413 CT genotype group relative to CC genotype, though due to
modest numbers in the latter group this would require independent verification. It is likely that folic
acid supplementation in the study cohort to mitigate toxicity of MTX has reduced the frequency of
observable side effects.
Sulfasalazine is metabolized by intestinal bacteria, resulting in the release of sulfapyridine (SPY)
and 5-aminosalicylate or 5-ASA (SPY and 5ASA are linked by an azo bond) [35]. Sulfapyridine is
almost completely absorbed by the colon, metabolized by the liver, and renally excreted [1]. Commonly
reported side-effects of sulfapyridine are minor gastrointestinal (GI) and central nervous system (CNS)
abnormalities, and uncommon serious haematological and hepatic side-effects [36,37]. Although study
participants with the AA and GA alleles of the rs17421511 SNP indicate higher mean plasma levels of
sulfapyridine compared to those with the GG allele (Figure S1), no significant adverse phenotypic
effects were observed in these subgroups.
The modest number of patients with the AA genotype of the rs17421511 SNP in our study
report significantly lower levels of pain and disease activity, relative to the remaining methotrexate
treated cohort. In future research with expanded patient cohorts, it would be pertinent to see if this
phenomenon is observed in other patient groups carrying this particular genotype. As a general
observation, a limitation of the current study is the low number of participants in particular genotype
groups and the smoking status was not recorded, which may impact upon methotrexate metabolism.
Furthermore, the findings for the methotrexate treated cohort are only generalizable to the European
population, as no significant differences in Hardy–Weinberg equilibrium were found by Chi-square
test between the dbGAP frequencies and those observed in this study.
While it is challenging to find a clear-cut relationship between genotype and circulating drug
levels which translates through to a clear prediction of phenotypic consequence, useful leads are
presented in the current study. The rs1476413 and rs17421511 MTHFR variants and the rs2231142
ABCG2 variant display significant changes which are consistent at both study time points.
With further carefully powered studies of variability in both csDMARD response and
predisposition to side effects, there is considerable potential to personalise effective treatments
whilst avoiding any toxicity.
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